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Introduction {#sec1}
============

Cells are constantly exposed to genotoxic stress and respond by activating dedicated DNA damage signaling and repair pathways that safeguard genome stability ([@bib17], [@bib32], [@bib34]). DNA damage signaling consists in the activation of checkpoint kinase cascades upon DNA damage detection and/or processing to coordinate cell-cycle progression with DNA repair ([@bib41]). Adding another layer of complexity, damage signaling and repair machineries operate on chromatin substrates in eukaryotic cell nuclei, where DNA wraps around histone proteins ([@bib44]). Chromatin landscapes, defined by specific patterns of histone variants ([@bib15]), post-translational modifications ([@bib10]), and various degrees of chromatin folding, convey epigenetic information that instructs cell function and identity through the regulation of gene expression and replication programs ([@bib7]). While the importance of maintaining epigenome integrity is widely recognized, it is still poorly understood how this is achieved during the DNA damage response.

DNA damage signaling and repair indeed elicit profound chromatin rearrangements, challenging epigenome maintenance ([@bib18]), with a transient destabilization of chromatin organization, accompanied by DNA-damage-induced changes in histone modifications ([@bib19]). Chromatin structure is then restored concomitantly with the repair of DNA damage ([@bib60], [@bib68]). It remains unclear whether chromatin restoration is an entirely faithful process or if genotoxic stress responses alter the epigenetic landscape, leaving a signature of DNA damage repair. Restoration of chromatin at damage sites involves the deposition of newly synthesized histones, as shown for H2A, H3.1, and H3.3 histone variants at sites of UVA and UVC damage in human cells ([@bib2], [@bib21], [@bib36], [@bib46], [@bib61]). New histone deposition employs dedicated histone chaperones, including the H3 variant-specific chaperones HIRA (histone regulator A) and CAF-1 (chromatin assembly factor 1) that operate at UVC damage sites ([@bib2], [@bib61]), while the histone chaperone FACT (facilitates chromatin transcription) controls H2A-H2B turnover ([@bib21]). Regarding the histone variant H2A.Z, its dynamic exchange at sites of DNA double-strand breaks (DSBs) in human cells involves the concerted action of the histone chaperone ANP32E (acidic nuclear phosphoprotein 32 family member E) and of the chromatin remodeling factors p400 and INO80 (inositol-requiring 80) ([@bib6], [@bib28], [@bib74]).

Here, we investigate how such repair-coupled chromatin rearrangements may leave an imprint on the epigenetic landscape and cross-talk with damage signaling by focusing on the H2A.X histone variant, which represents the ancestral form of H2A, conserved in all eukaryotes ([@bib69]). Making up only 10%--25% of total H2A, H2A.X is nevertheless central to the DNA damage response, owing to a particular C-terminal serine, in position 139 in mammals, targeted by DNA-damage-responsive kinases ([@bib64]). H2A.X S139 phosphorylation spreads at a distance from the damage, which is key for amplifying the DNA damage signal through the coordinated recruitment of DNA damage checkpoint mediators ([@bib8], [@bib67]). Best described in response to DSBs, this signaling cascade also operates following other types of genomic insults, including UV irradiation. UV damage processing triggers checkpoint signaling by activating the ATR (ataxia-telangiectasia-mutated and Rad3-related) kinase, which phosphorylates H2A.X ([@bib29]). This in turns recruits checkpoint mediators, including MDC1 (mediator of DNA damage checkpoint 1) and downstream factors that control, among others, 53BP1 (p53-binding protein 1) accumulation ([@bib50]).

Regardless of which type of DNA insult activates the H2A.X signaling cascade, a salient feature of H2A.X phosphorylation is that it takes place *in situ* in damaged chromatin ([@bib64]). The original distribution of H2A.X in chromatin is thus a critical determinant of the damage response, as it will govern the distribution of the phosphorylated form, known as γH2A.X. A commonly held view is that H2A.X is phosphorylated at DNA damage sites but ubiquitously incorporated in chromatin, independently of DNA damage. However, recent chromatin immunoprecipitation sequencing (ChIP-seq) studies in mammalian cells challenged this view by revealing a nonrandom distribution of H2A.X, with enrichments at active transcription start sites and sub-telomeric regions in activated human lymphocytes ([@bib65], [@bib66]) and at extra-embryonic genes in mouse pluripotent stem cells ([@bib73]). The mechanisms underpinning the nonrandom distribution of H2A.X in chromatin are unknown, as is their potential connection to the DNA damage response.

In this study, by investigating H2A.X dynamics during UVC damage repair in mammalian cells, we reveal that H2A.X is deposited *de novo* in damaged chromatin by the histone chaperone FACT, concomitantly with repair synthesis. We also uncover H2A.Z eviction from UV-damaged chromatin by ANP32E, which, together with FACT-mediated H2A.X deposition, reshapes the chromatin landscape by altering histone variant patterns at repair sites. Functionally, both histone chaperones are key for mounting an efficient cellular response to DNA damage, with FACT potentiating H2A.X-dependent damage signaling.

Results {#sec2}
=======

*De Novo* Deposition of H2A Histone Variants at Repair Sites {#sec2.1}
------------------------------------------------------------

To characterize H2A.X deposition pathways, we monitored *de novo* histone deposition using SNAP-tag technology ([@bib13]) in human U2OS cells stably expressing SNAP-tagged H2A variants ([Figure 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}). Our initial analyses did not reveal any detectable accumulation of new H2A variants at UVC damage sites, contrary to what we had observed with newly synthesized H3.3 ([@bib2]) ([Figure 1](#fig1){ref-type="fig"}B). We reasoned that this discrepancy might be due to the higher mobility of outer core histones (H2A-H2B) compared to inner core histones (H3-H4) ([@bib39], [@bib43]), which may hinder the detection of their local accumulation. Because outer core histone mobility is partly transcription dependent ([@bib33], [@bib39]), we tracked new histones in the presence of transcription inhibitors, 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB), flavopiridol, or α-amanitin ([@bib12]) ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}A). Note that short-term transcription inhibition reduces but does not abolish histone neosynthesis because of preexisting mRNAs. Thus, we revealed new H2A.X accumulation at sites of UVC damage in the vast majority of cells (\>85%; [Figures 1](#fig1){ref-type="fig"}C--1E). We recapitulated our observations in mouse embryonic fibroblasts ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). Importantly, new H2A.X accumulation at UVC damage sites was not an artifact of transcription inhibition, as it was also detectable in the absence of transcription inhibitors upon exposure to higher UVC doses, with a modest but reproducible enrichment at UV sites relative to the whole nucleus approaching 1.2-fold ([Figure S2](#mmc1){ref-type="supplementary-material"}B). No significant enrichment was observed when staining for total H2A.X ([Figure 1](#fig1){ref-type="fig"}D), arguing that new H2A.X accumulation most likely reflects histone exchange at damage sites. Noteworthy, *de novo* accumulation of H2A.X was also observed at sites of UVA laser micro-irradiation ([Figure S2](#mmc1){ref-type="supplementary-material"}C) and thus is not unique to the UVC damage response. We clarified the nature of the DNA damage that was driving new H2A.X deposition upon UVC irradiation by showing that UVC did not elicit DSB signaling ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Thus, the new H2A.X deposition observed at UVC damage sites is unlikely to be driven by DSBs. To test whether it was specific for the damage-responsive histone H2A.X, we extended our analyses to other H2A variants, namely canonical H2A and another replacement variant conserved in all eukaryotes, H2A.Z, considering both H2A.Z.1 and H2A.Z.2 forms, which display different dynamics in response to UVA laser damage in human cells ([@bib55]). For this, we established U2OS cell lines that stably express comparable levels of SNAP-tagged H2A variants ([Figure S1](#mmc1){ref-type="supplementary-material"}). We detected *de novo* accumulation of H2A, but not of H2A.Z.1 and H2A.Z.2, at UVC damage sites ([Figure 1](#fig1){ref-type="fig"}E). Similar results were obtained without transcription inhibition ([Figure S2](#mmc1){ref-type="supplementary-material"}E), pointing to a specific histone deposition mechanism that is not general to all H2A variants.Figure 1De Novo Accumulation of H2A Variants at UVC Damage Sites(A) Assay for monitoring the accumulation of newly synthesized histones labeled with tetramethylrhodamine (TMR)-star at UVC damage sites marked by the repair factor XPA (xeroderma pigmentosum, complementation group A) in human cells stably expressing SNAP-tagged histones.(B--E) New histone accumulation at UVC damage sites marked by XPA analyzed 2 hr after irradiation in U2OS cells stably expressing the indicated SNAP-tagged histone variants, wild-type (B--D) and mutants (E).Cells were treated without (B) or with (C) RNAPII inhibitors (DRB; FLV, flavopiridol; AMA, α-amanitin; DMSO and PBS, vehicles). Total H2A.X is detected by immunostaining for SNAP or H2A.X (D). S139A/E, phospho-deficient/mimetic mutant; WT, wild-type. Bar chart shows mean ± SD from 2 independent experiments. Scale bars, 10 μm.ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figures S1--S4](#mmc1){ref-type="supplementary-material"}.

Collectively, these data reveal a transcription-independent deposition of newly synthesized H2A and H2A.X, but not H2A.Z, histone variants at repair sites.

New H2A.X Deposition at Repair Sites Is Independent of S139 Phosphorylation {#sec2.2}
---------------------------------------------------------------------------

We next examined the importance of H2A.X S139 phosphorylation for new H2A.X deposition at repair sites. We verified that the C-terminal SNAP tag did not prevent H2A.X phosphorylation (data not shown). By comparing the dynamics of H2A.X wild-type to phospho-mimetic (S139E) and phospho-deficient (S139A) mutants, we established that new H2A.X accumulation at sites of UVC damage repair occurred irrespective of H2A.X S139 phosphorylation status ([Figure 1](#fig1){ref-type="fig"}E). Since SNAP-tagged H2A.X proteins are expressed in the context of wild-type endogenous H2A.X, we also treated cells with an ATR kinase inhibitor, which inhibited UV-induced phosphorylation of all H2A.X forms but did not impair the *de novo* deposition of H2A.X at UVC-damage sites ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Thus, H2A.X phosphorylation is dispensable for the deposition of new H2A.X at sites of DNA damage repair.

*De Novo* Deposition of H2A Histone Variants at Replication Foci {#sec2.3}
----------------------------------------------------------------

During the course of our analyses, we noticed that new H2A.X displayed a punctuate pattern in a subset of undamaged cells upon transcription inhibition. This deposition pattern corresponded to replication foci in S phase cells, as shown by co-staining with the replication-coupled histone chaperone CAF-1 ([Figure 2](#fig2){ref-type="fig"}A). We observed new H2A.X accumulation at replication foci throughout S phase in U2OS cells treated with transcription inhibitors ([Figure 2](#fig2){ref-type="fig"}B). In mouse embryonic fibroblasts, transcription inhibitors could be omitted to visualize new H2A.X accumulation in replicating heterochromatin domains, which are poorly transcribed by nature ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). As observed at repair sites, the enrichment at replication foci was specific for newly synthesized H2A.X ([Figure 2](#fig2){ref-type="fig"}C) and only detected for H2A and H2A.X, but not H2A.Z variants ([Figure 2](#fig2){ref-type="fig"}D).Figure 2*De Novo* Accumulation of H2A Variants at Replication Foci(A--D) New histone accumulation at replication foci marked by CAF-1 p150 analyzed in U2OS cells stably expressing SNAP-tagged H2A.X, wild-type form (A--C) or different H2A variants (D) and treated with the indicated RNAPII inhibitors (DRB, flavopriridol \[FLV\], α-amanitin \[AMA\], and DMSO and PBS \[vehicles\]). Replication patterns (B) distinguish early, mid-, and late S phase cells. Total H2A.X is detected by immunostaining for SNAP or H2A.X (C). Bar chart, mean ± SD from 2 independent experiments. Scale bars, 10 μm. ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

These findings demonstrate that newly synthesized H2A and H2A.X are deposited both at repair sites and at replication foci.

New H2A.X Deposition Is Coupled to Replicative and Repair Synthesis {#sec2.4}
-------------------------------------------------------------------

To dissect the mechanisms underlying new H2A.X deposition at repair sites and replication foci, we investigated a possible dependency on DNA synthesis, which is a common feature of both responses. We prevented repair synthesis by downregulating the late repair factor XPG (xeroderma pigmentosum, group G), an endonuclease involved in the excision of the UVC-damaged oligonucleotide, which is a prerequisite for repair synthesis ([Figure 3](#fig3){ref-type="fig"}A). XPG knockdown did not impede damage detection by early repair factors but markedly reduced the accumulation of newly synthesized H2A.X at sites of UVC damage ([Figure 3](#fig3){ref-type="fig"}B), with no detectable effect on new H2A.X deposition at replication foci (data not shown). We confirmed that new H2A.X deposition at repair sites was dependent on the DNA synthesis machinery by knocking down the DNA polymerase processivity factor PCNA (proliferating cell nuclear antigen; [Figures 3](#fig3){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B). We also uncovered a dependency on DNA synthesis for new H2A.X deposition at replication foci by inhibiting replicative synthesis with aphidicolin ([Figure 3](#fig3){ref-type="fig"}D). These results indicate that the deposition of newly synthesized H2A.X at replication foci and UVC damage sites is dependent on replicative and repair synthesis machineries.Figure 3New H2A.X Accumulation at UV Sites and Replication Foci Is Coupled to DNA Synthesis(A) Scheme: XPG's role in the late steps of UVC damage repair. Percentage of cells showing repair synthesis (EdU) at UVC-damage sites (CPDs \[cyclobutane pyrimidine dimers\]) in U2OS cells treated with the indicated siRNAs (siLUC, control). At least 200 cells were scored in 2 independent experiments.(B and C) New H2A.X accumulation at UVC damage sites marked by XPA or XPB analyzed 2 hr after irradiation in the presence of flavopiridol (+FLV) in U2OS H2A.X-SNAP cells treated with siRNAs targeting XPG (B) or PCNA (C) (siLUC, control). Knockdown efficiencies are verified by western blot and by impaired CAF-1 recruitment to damage sites.(D) New H2A.X accumulation at replication foci (marked by EdU before aphidicolin addition) in U2OS H2A.X-SNAP cells treated with flavopiridol (+FLV) and the replication inhibitor aphidicolin (Aphi). Replication inhibition is shown by impaired CAF-1 recruitment to EdU foci.Bar charts show mean ± SD from at least 2 independent experiments. Scale bars, 10 μm. ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

New H2A.X Deposition Is Not Coupled to New H3 Deposition {#sec2.5}
--------------------------------------------------------

We next investigated whether new H2A.X deposition was coordinated with the deposition of newly synthesized H3 variants that occurs at replication and repair sites ([@bib2], [@bib61], [@bib62]). Knocking down the histone chaperone CAF-1, responsible for new H3.1 deposition at UV sites ([@bib61]), did not significantly affect new H2A.X accumulation at sites of UVC damage repair ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Similar results were obtained upon downregulation of the histone chaperone HIRA, which deposits new H3.3 at UV sites ([@bib2]) ([Figure S4](#mmc1){ref-type="supplementary-material"}C) and upon loss of function of both pathways simultaneously (data not shown). These data demonstrate that new H2A.X deposition occurs independently of new H3 deposition by CAF-1 and HIRA at UVC damage sites.

The Histone Chaperone FACT Promotes New H2A.X Deposition at UV Damage Sites {#sec2.6}
---------------------------------------------------------------------------

To uncover the molecular determinants of new H2A.X accumulation at sites of UVC damage repair, we examined the effect of knocking down candidate histone chaperones and chromatin remodelers, focusing on FACT and INO80. Indeed, the latter maintains the levels of chromatin-bound H2A.X in human cells ([@bib66]) and promotes H2A deposition in yeast ([@bib59]), while FACT incorporates H2A and H2A.X, but not H2A.Z, into chromatin ([@bib30]) and stimulates H2A turnover at UVC damage sites in human cells ([@bib21]). Moreover, FACT associates with replisome components in human cells ([@bib4], [@bib70]), is involved in replication-coupled nucleosome assembly in yeast ([@bib75]), and is critical for replisome progression through chromatin *in vitro* ([@bib40]). Interestingly, like new H2A.X deposition, FACT recruitment to replication foci was abrogated upon aphidicolin treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}A), and FACT accumulation at repair sites was impaired by XPG and PCNA knockdowns ([Figure 4](#fig4){ref-type="fig"}A--4C). Consistent with a dependency on late repair steps, FACT recruitment to UV damage sites peaked 2--4 hr after UV irradiation ([Figure S5](#mmc1){ref-type="supplementary-material"}B). FACT recruitment was independent of H2A.X phosphorylation by ATR ([Figure S5](#mmc1){ref-type="supplementary-material"}C), similar to new H2A.X deposition. Furthermore, FACT trapping to chromatin by the intercalating agent curaxin CBL0137 ([@bib27]) ([Figure S5](#mmc1){ref-type="supplementary-material"}D) impaired FACT accumulation and new H2A.X deposition at UVC damage sites ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). In line with these findings, siRNA-mediated downregulation of both FACT subunits, but not of the remodeler INO80, markedly reduced new H2A.X deposition at UVC damage sites ([Figures 4](#fig4){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}G, left). This effect was specific for the histone chaperone FACT, as depletion of NAP-1 (Nucleosome Assembly Protein-1) family chaperones, which similarly handle H2A variants ([@bib58]), did not impair new H2A.X deposition at repair sites ([Figure S4](#mmc1){ref-type="supplementary-material"}D). The decrease in new H2A.X deposition upon FACT knockdown was also observed in the whole nucleus, most likely reflecting replication- and transcription-coupled deposition of H2A.X by FACT, and cannot be explained by reduced histone neo-synthesis, as FACT knockdown did not inhibit nascent transcription ([Figure S5](#mmc1){ref-type="supplementary-material"}H). *De novo* accumulation of H2A was similarly reduced in FACT knockdown cells ([Figure S5](#mmc1){ref-type="supplementary-material"}I). These results establish that FACT promotes both new H2A and H2A.X deposition at repair sites.Figure 4The Histone Chaperone FACT Promotes New H2A.X Deposition at UV Damage Sites(A) Recruitment of FACT subunits SSRP1 and SPT16 to repair sites 2 hr after local UVC irradiation in U2OS cells. Scheme: FACT complex bound to H2A-H2B.(B--D) Accumulation of FACT subunit SSRP1 and new H2A.X at repair sites marked by XPA/XPB analyzed 2 hr (B and C) or 1.5 hr (D) after local UVC irradiation in U2OS or U2OS H2A.X-SNAP cells treated with the indicated siRNAs (siLUC, control; siFACT, siSPT16 + siSSRP1). Knockdown efficiencies are verified by western blot.Bar charts represent mean ± SD from at least 2 independent experiments. Scatterplots show mean ± SD from at least 100 cells (1 representative experiment out of 3). Scale bars, 10 μm. ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

H2A.Z Removal Precedes New H2A.X Deposition in UVC-Damaged Chromatin {#sec2.7}
--------------------------------------------------------------------

In contrast to H2A and H2A.X, H2A.Z is not deposited *de novo* at repair sites ([Figure 1](#fig1){ref-type="fig"}E), which may impact histone variant patterns in UVC-damaged chromatin. Supporting this idea, when we stained for total histones, we observed that while H2A and H2A.X total levels were not detectably altered, H2A.Z total levels were reduced by ∼10% in damaged chromatin ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S6](#mmc1){ref-type="supplementary-material"}A). This reduction was detectable with different antibodies targeting H2A.Z (N and C termini) and upon fluorescent labeling of total H2A.Z.1- and H2A.Z.2-SNAP ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S6](#mmc1){ref-type="supplementary-material"}B), ruling out the possibility of impaired detection due to post-translational modification of H2A.Z. Such selective depletion affecting H2A.Z, but not H2A and H2A.X, is unlikely to result from a local decompaction of chromatin at damage sites and is not a mere consequence of transcription inhibition at UV sites, because inhibiting transcription did not significantly diminish the levels of chromatin-bound H2A.Z ([Figure S6](#mmc1){ref-type="supplementary-material"}C). When exploring the molecular determinants of H2A.Z removal, we found that it occurred independently of INO80 and FACT ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}G, right), showing that new H2A.X deposition by FACT is dispensable for H2A.Z removal. Interestingly however, H2A.Z depletion from UV-damaged chromatin was dependent on the histone chaperone ANP32E ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}G, right, and [S6](#mmc1){ref-type="supplementary-material"}D), previously characterized for its ability to remove H2A.Z from chromatin ([@bib49], [@bib56]). To gain further mechanistic insights, we analyzed the relative kinetics of H2A.Z removal by ANP32E and new H2A.X deposition by FACT at repair sites by co-staining for both histone variants. We observed that new H2A.X deposition peaked between 1 and 2 hr after irradiation and returned close to basal levels 6 hr after UVC irradiation ([Figure 5](#fig5){ref-type="fig"}C). H2A.Z removal reached a maximum ∼30 min after UVC irradiation, clearly preceding new H2A.X deposition ([Figure 5](#fig5){ref-type="fig"}C). Notably however, ANP32E-mediated removal of H2A.Z was dispensable for FACT recruitment and new H2A.X deposition at UVC damage sites ([Figures 5](#fig5){ref-type="fig"}D and 5E). Thus, ANP32E and FACT chaperones independently orchestrate histone variant turnover in UVC-damaged chromatin, resulting in the maintenance of H2A.X and the loss of H2A.Z. New H2A.X enrichment at UV sites did not persist long-term after UVC irradiation, most likely due to the gradual incorporation of new H2A.X in the entire nucleus over time (data not shown). Nevertheless, it was detectable in early G1 cells that had been damaged in late G2 of the previous cell cycle ([Figure S4](#mmc1){ref-type="supplementary-material"}E), suggesting that new H2A.X enrichment might be maintained through mitosis and contribute to bookmarking repair sites.Figure 5The Histone Chaperone ANP32E Promotes H2A.Z Removal from UV Damage Sites(A and B) Distribution of the indicated H2A variants (total levels, TMR pulse or H2A.Z Nt/Ct antibody) analyzed 1 hr after local UVC irradiation in U2OS cells expressing SNAP-tagged histones (A) and treated with the indicated siRNAs (B) (siLUC, control; siFACT, siSPT16 + siSSRP1). Arrowheads indicate UV irradiation sites. Fluorescence intensities are measured along the dotted lines. Scatterplots show mean ± SD from at least 40 cells (1 representative experiment out of 3). The significance of H2A.Z loss or enrichment at UV sites is indicated.(C) Enrichment of new H2A.X and loss of total H2A.Z at UV sites (marked by CPD) analyzed at the indicated time points post 500 J/m^2^ local UVC irradiation in U2OS H2A.X-SNAP cells. Scatterplots show mean ± SD from at least 39 UV spots (1 representative experiment out of 2). Significance is given compared to a theoretical mean of 1.(D and E) Accumulation of FACT subunit SSRP1 (D) and new H2A.X (E) at repair sites analyzed as in [Figures 4](#fig4){ref-type="fig"}B--4D. Percentages of cells recruiting FACT to repair sites are shown (from at least 250 cells scored in 2 independent experiments).Scatterplots show mean ± SD from at least 70 cells (1 representative experiment out of 2). Knockdown efficiencies were verified by western blot. Scale bars, 10 μm. ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

FACT Potentiates H2A.X-Dependent Signaling of DNA Damage {#sec2.8}
--------------------------------------------------------

Having identified FACT and ANP32E as key factors for H2A.Z and H2A.X turnover in damaged chromatin, we set out to determine the functional relevance of this mechanism. We observed that both FACT and ANP32E knockdowns conferred increased sensitivity of cells to UVC damage ([Figure 6](#fig6){ref-type="fig"}A), suggesting that the histone variant turnover orchestrated by these two chaperones may be functionally important for an efficient DNA damage response. However, downregulation of FACT or ANP32E did not reveal any significant contribution of these chaperones to UVC damage repair, as shown by efficient repair factor recruitment ([Figures 4](#fig4){ref-type="fig"}D, [5](#fig5){ref-type="fig"}B, 5D, 5E, [S5](#mmc1){ref-type="supplementary-material"}I, and [S6](#mmc1){ref-type="supplementary-material"}D) and unaltered repair synthesis ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). In addition, FACT depletion did not affect the timely removal of UV photoproducts ([Figure S7](#mmc1){ref-type="supplementary-material"}C), and preventing new H2A.X synthesis by siRNA ([Figure S7](#mmc1){ref-type="supplementary-material"}D) did not impair UVC damage repair synthesis ([Figure S7](#mmc1){ref-type="supplementary-material"}E), arguing that new H2A.X deposition by FACT is dispensable for UVC damage repair.Figure 6FACT Potentiates H2A.X-Dependent Signaling of DNA Damage(A) Clonogenic survival of U2OS cells treated with the indicated siRNAs (siLUC, control) in response to global UVC irradiation (mean ± SD from 4 independent experiments).(B--E) Quantification of damage signaling factors γH2A.X (B), MDC1 (C), 53BP1 (D), and ATR (E) at sites of UVC damage repair (EdU spots) 2 hr after local UVC irradiation in U2OS cells treated with the indicated siRNAs (siLUC, control). Scatterplots show mean ± SD from at least 78 UV spots (1 representative experiment out of 3). Knockdown efficiencies and total levels of damage signaling factors are controlled by western blot. Scale bars, 10 μm.ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

We next investigated a potential impact of these chaperones on UVC damage signaling. To avoid misinterpretation of the data due to the interference of FACT knockdown with DNA replication, we restricted our analysis to nonreplicating cells based on EdU (5-ethynyl-2′-deoxyuridine) staining. Thus, we noticed that γH2A.X levels were reduced by 30%--35% at sites of UVC damage repair in FACT-depleted cells ([Figure 6](#fig6){ref-type="fig"}B), while H2A.X total levels did not show any measurable decrease as assessed in total cell extracts and at damage sites ([Figure 6](#fig6){ref-type="fig"}B; data not shown). The reduction in γH2A.X was not explained by lower damage infliction or diminished repair, because repair synthesis and repair factor recruitment were not significantly affected (data not shown). In contrast to FACT loss of function, ANP32E depletion had no inhibitory effect on γH2A.X levels at UVC damage sites ([Figure 6](#fig6){ref-type="fig"}B). We next analyzed the recruitment to damaged chromatin of downstream damage signaling factors, including the checkpoint mediators MDC1 and 53BP1. These factors also showed 30%--40% reduction at UVC damage sites in FACT knockdown cells, while their total levels were not decreased ([Figures 6](#fig6){ref-type="fig"}C--6D), indicating that FACT is relevant to not only early but also late damage-signaling events. This function of FACT may rely, at least in part, on its ability to promote new H2A.X deposition at repair sites. However, we do not exclude that other FACT activities and/or associated factors may also contribute to H2A.X-dependent signaling. Supporting this idea, we observed reduced recruitment of the ATR kinase to UV damage sites in FACT-depleted cells ([Figure 6](#fig6){ref-type="fig"}E). Collectively, these results establish that FACT and ANP32E histone chaperones are critical for the cells to mount an efficient DNA damage response with FACT stimulating H2A.X-dependent signaling of DNA damage.

Discussion {#sec3}
==========

By analyzing the dynamics of H2A histone variants in UV-damaged chromatin, we have uncovered a H2A.Z and H2A.X turnover reaction controlled by two histone chaperones, ANP32E and FACT ([Figure 7](#fig7){ref-type="fig"}). Chromatin restoration after repair thus entails at least short-term reshaping of the chromatin landscape with a change in histone variant pattern. We also reveal that H2A.X is deposited *de novo* at repair sites, which may constitute an extra level of regulation for fine-tuning the DNA damage response in addition to the well-characterized phosphorylation of H2A.X. By ensuring that the target for DNA damage checkpoint kinases is present in sufficient amount and at the right place, new H2A.X deposition may allow an efficient and timely response to genotoxic insults in chromatin regions that are susceptible to DNA damage.Figure 7Model for Chromatin Reshaping during UVC Damage Repair by ANP32E and FACT Histone ChaperonesANP32E removes H2A.Z from damaged chromatin, which may enhance chromatin accessibility. FACT subsequently promotes new H2A.X deposition coupled to repair synthesis and potentiates DNA damage signaling, thus contributing to coordinate signaling and repair of DNA damage. The resulting distribution of H2A.X in chromatin reflects DNA damage experience.

New H2A.X Deposition at Sites of DNA Synthesis during Replication and Repair {#sec3.1}
----------------------------------------------------------------------------

The selective deposition of H2A and H2A.X variants and not H2A.Z at sites of UVC damage repair parallels our previous findings on H3 variants, indicating that H3.1 and H3.3 are deposited *de novo* in UVC-damaged chromatin while CENP-A is not ([@bib2], [@bib61]). However, new H2A.X and new H3 deposition at repair sites are uncoupled, suggesting that new H2A.X-H2B associate with parental H3-H4 in repaired chromatin. A selective deposition of H2A variants also occurs on replicating DNA, as previously observed for H2A versus H2A.Z in mouse pericentric heterochromatin ([@bib14]) and in proteomic studies of human histone variants associated with replicating DNA ([@bib5]). The coupling between new H2A.X deposition and DNA replication is intriguing given that H2A.X is not a prototypical replicative histone variant ([@bib72]). Nevertheless, the lack of introns and the existence of a non-polyadenylated form of *H2A.X* mRNA, both characterizing replicative histone transcripts, place H2A.X in a unique position between replicative and replacement histone variants ([@bib48]). Functionally, the deposition of newly synthesized H2A.X at replication foci may ensure that H2A.X is not gradually lost during replication, which would happen if only the bona fide replicative variant H2A was deposited. Such replication-coupled deposition of H2A.X could explain the increase in soluble H2A.X in human cells treated with replication inhibitors ([@bib42]). The *de novo* deposition of H2A.X at repair sites may provide a molecular basis for the H2A.X hotspots found in chromatin regions that are susceptible to endogenous damage ([@bib66]). We speculate that the enrichment of H2A.X may reflect recurrent genomic insults, with H2A.X marking chromatin regions that are prone to damage to facilitate subsequent damage responses. Noteworthy, the H2A.X protein is rapidly stabilized following DNA damage, contributing to a local enrichment at repair sites ([@bib9]). However, this stabilization requires H2A.X phosphorylation on Ser139, while new H2A.X deposition at repair sites does not. Thus, these appear to be two distinct and complementary mechanisms controlling the distribution of H2A.X in chromatin, which reflects DNA damage experience.

Role of the Histone Chaperone FACT in New H2A.X Deposition {#sec3.2}
----------------------------------------------------------

We have identified FACT as the responsible histone chaperone for new H2A and H2A.X deposition at repair sites. Interestingly, FACT also promotes the deposition of another H2A variant, macroH2A1.2, at sites of replication stress in mammalian cells ([@bib38]). FACT-mediated deposition of new H2A.X at UV damage sites is dependent on PCNA. This is reminiscent of the recruitment of CAF-1 to damaged DNA ([@bib52]), putting forward PCNA as a platform for histone chaperones on damaged chromatin. FACT may directly associate with PCNA, as the FACT subunit SSRP1 (structure-specific recognition protein 1) harbors a non-canonical PIP (PCNA-interacting protein) box ([@bib47]). Alternatively, FACT's interaction with PCNA could be mediated by PCNA-binding factors like XRCC1 (X-ray repair cross-complementing protein 1) ([@bib24]), which contributes to UVC damage repair ([@bib53]) and was recently reported to associate with FACT ([@bib26]). Other replisome components cooperating with FACT, like MCM (minichromosome maintenance) proteins ([@bib70]), could also contribute to FACT recruitment to sites of UV damage repair.

Impact of New H2A.X Deposition on DNA Damage Signaling and Repair {#sec3.3}
-----------------------------------------------------------------

Although deposited *de novo* at sites of UVC damage, H2A.X is not required for repair. These findings are in line with previous work showing that H2A.X knockout mouse cells are not particularly sensitive to UV irradiation ([@bib11]). Similarly, the histone chaperone FACT is dispensable for global genome repair synthesis at UV damage sites. This contrasts with FACT requirement for replicative DNA synthesis ([@bib1], [@bib40], [@bib57]), suggesting that FACT activity is more critical for replication fork progression through chromatin than for DNA synthesis per se.

We find that FACT coordinates DNA repair synthesis with damage signaling. While the histone chaperones ASF1 and CAF-1 are required for turning off DSB signaling ([@bib16], [@bib20], [@bib37]), FACT in contrast enhances γH2A.X levels at sites of UV damage repair, thus potentiating damage signaling. It is not clear at this stage if FACT function in damage signaling governs cell resistance to UV damage or if this also relies on other FACT-dependent activities, including a putative contribution to transcription-coupled repair of UV damage. It is tempting to speculate that FACT stimulates damage signaling, at least in part, through new H2A.X deposition. While this does not lead to a measurable increase in H2A.X total levels at repair sites, it may be enough to amplify the γH2A.X signal by facilitating H2A.X phosphorylation spreading. The repair-coupled deposition of H2A.X may thus contribute to keep damage signaling on while DNA repair is still ongoing. It may also be functionally important for subsequent damage responses by maintaining critical levels of H2A.X in damage-prone chromatin regions.

H2A.Z and H2A.X Turnover at Sites of DNA Damage Repair {#sec3.4}
------------------------------------------------------

New H2A.X deposition at sites of UV damage repair is preceded by the removal of H2A.Z, resulting in a local change in histone variant pattern. It still remains to be determined if the histone variant turnover takes place at the level of the nucleosome, with H2A.X replacing H2A.Z, or at the level of the damaged chromatin domain. H2A.Z is removed from UVC-damaged chromatin by ANP32E, reminiscent of what observed in response to UVA laser damage ([@bib28]). However, in this case, H2A.Z returns to basal levels in damaged chromatin after a transient accumulation, while H2A.Z is depleted at UVC damage sites. Furthermore, while ANP32E accumulates on laser tracks ([@bib28]), we did not observe a detectable enrichment of ANP32E at UVC damage sites (data not shown). This histone chaperone may thus be very transiently and/or loosely associated with UVC-damaged chromatin to remove H2A.Z. We did not find any significant role for the remodeler INO80 in H2A.Z removal from UVC-damaged chromatin, contrasting with observations at UVA laser tracks in human cells ([@bib6]), arguing that different types of DNA lesions may engage distinct chromatin remodeling machineries.

ANP32E promotes cell survival to UVC irradiation, suggesting that ANP32E-mediated removal of H2A.Z from UVC-damaged chromatin may be of functional importance. Given that H2A.Z increases chromatin folding *in vitro* ([@bib23], [@bib25]) and is rapidly removed from UVC-damaged chromatin, the local depletion of H2A.Z could contribute to the early chromatin relaxation observed at UVC damage sites ([@bib3], [@bib45]). Future studies will help decipher the functional contribution of H2A.Z displacement to the UV damage response and dissect potential cross-talk with other histone variant dynamics in damaged chromatin.

Dynamics of H2A Variants at Repair Sites and Transcription Regulation {#sec3.5}
---------------------------------------------------------------------

FACT regulates transcription recovery after UVC damage in human cells ([@bib21]). Thus, FACT-mediated deposition of H2A variants at repair sites could coordinate repair synthesis with transcription restart. Tipping the balance toward H2A and H2A.X as opposed to H2A.Z may also help keeping transcription in check and avoid transcription interference with repair, because H2A.Z poises genes for transcription activation and promotes cryptic transcription when mislocalized in yeast ([@bib35], [@bib76]). H2A.Z and H2A.X histone variant turnover at UV sites may thus contribute to mitigate transcription-repair conflicts by maintaining transcription inhibition during repair synthesis. Notably, FACT was shown to limit the formation of RNA-DNA hybrids in yeast and human cells ([@bib31]). It will be of major interest to investigate whether this function of FACT relies on H2A histone variant deposition on newly synthesized DNA. Several recent studies have uncovered a critical role for H2A.X in silencing specific sets of genes during mammalian cell differentiation ([@bib73], [@bib71]). Therefore, alterations in H2A.X distribution following DNA damage may impact cell fate determination via the rewiring of transcriptional programs, thus contributing to the reported effect of DNA damage repair on cell differentiation and reprogramming ([@bib63]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-ANP32ESigma-AldrichCat\# SAB2100124; RRID: [AB_10602824](nif-antibody:AB_10602824){#interref0010}Anti-ANP32EMyBioSourceCat\# MBS9214243Anti-CPDKamiya Biomedical CompanyCat\# MC-062; RRID: [AB_1233355](nif-antibody:AB_1233355){#interref0015}Anti-H2A.XAbcamCat\# ab11175; RRID: [AB_297814](nif-antibody:AB_297814){#interref0020}Anti-γH2A.XMilliporeCat\# 05-636; RRID: [AB_309864](nif-antibody:AB_309864){#interref0025}Anti-γH2A.XCell Signaling technologyCat\# 2577; RRID: [AB_2118010](nif-antibody:AB_2118010){#interref0030}Anti-H2A.Z CtActive motifCat\# 39113; RRID: [AB_2615081](nif-antibody:AB_2615081){#interref0035}Anti-H2A.Z NtGeneTexCat\# GTX108298; RRID: [AB_1950475](nif-antibody:AB_1950475){#interref0040}Anti-INO80Bethyl LaboratoriesCat\# A303-371A; RRID: [AB_10950580](nif-antibody:AB_10950580){#interref0045}Anti-SNAPPierce AntibodiesCat\# CAB4255; RRID: [AB_10710011](nif-antibody:AB_10710011){#interref0050}Anti-SPT16 (FACT subunit)Santa Cruz BiotechnologyCat\# sc-28734; RRID: [AB_661341](nif-antibody:AB_661341){#interref0055}Anti-SSRP1 (FACT subunit)Ozyme BLE609701Cat\# BLE609701; RRID: [AB_315730](nif-antibody:AB_315730){#interref0060}Anti-XPABD BiosciencesCat\# 556453; RRID: [AB_396423](nif-antibody:AB_396423){#interref0065}Anti-XPBSanta Cruz BiotechnologyCat\# sc-293; RRID: [AB_2262177](nif-antibody:AB_2262177){#interref0070}**Chemicals, Peptides, and Recombinant Proteins**5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB)Sigma-AldrichCat\# D1916alpha-AmanitinSigma-AldrichCat\# A2263Flavopiridol hydrochloride hydrateSigma-AldrichCat\# F3055ATR inhibitor AZ20SelleckchemCat\# S7050ATM inhibitor KU55933Tocris BioscienceCat\# 3544AphidicolinSigma-AldrichCat\# A0781SNAP-Cell BlockNew England BiolabsCat\# S9106SSNAP-Cell TMR-StarNew England BiolabsCat\# S9105SParaformaldehydeElectron Microscopy SciencesCat\# 15710Triton X-100EuromedexCat\# 2000Vectashield medium with DAPIVector LaboratoriesCat\# H-1200**Critical Commercial Assays**Lipofectamine 2000InvitrogenCat\# 11668019Lipofectamine RNAiMAXInvitrogenCat\# 137780754%--20% Mini-PROTEAN TGX gelsBio-RadCat\# 4561096Click-iT EdU Alexa Fluor 594 Imaging kitInvitrogenCat\# C10339Click-iT RNA Imaging kitInvitrogenCat\# C10330**Deposited Data**Raw data filesThis study, Mendeley data<https://doi.org/10.17632/gz5xtcyxzj.1>**Experimental Models: Cell Lines**U2OSATCCCat\# HTB-96U2OS H2A.X-SNAP WT formThis studyN/AU2OS H2A.X-SNAP S139A mutantThis studyN/AU2OS H2A.X-SNAP S139E mutantThis studyN/AU2OS H2A.Z.1-SNAPThis studyN/AU2OS H2A.Z.2-SNAPThis studyN/AU2OS H2A-SNAPThis studyN/AU2OS H3.3-SNAP([@bib22])N/ANIH/3T3ATCCCat\# CRL-1658NIH/3T3 H2A.X-SNAP + GFP-DDB2This studyN/A**Oligonucleotides**siRNAs (Table in [Method Details](#sec4.4){ref-type="sec"})Eurofins MWG OperonN/A (custom sequences)**Recombinant DNA**H2A-SNAPThis studyN/AH2A.X-SNAP (WT)This studyN/AH2A.X-SNAP (S139A)This studyN/AH2A.X-SNAP (S139E)This studyN/AH2A.Z.1-SNAPThis studyN/AH2A.Z.2-SNAPThis studyN/AH3.3-SNAP([@bib22])N/AGFP-DDB2([@bib3])N/A**Software and Algorithms**MetamorphMolecular Devices<https://www.moleculardevices.com/products/cellular-imaging-systems/acquisition-and-analysis-software/metamorph-microscopy>ZenZeiss<https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html>ImageJNIH, USA<https://imagej.nih.gov/ij/>ICYInstitut Pasteur, France<http://icy.bioimageanalysis.org/>GraphPad PrismGraphPad software<https://www.graphpad.com/scientific-software/prism/>Adobe Photoshop CCAdobe<https://www.adobe.com/products/photoshop.html>FlowJoFlowJo<https://www.flowjo.com>**Other**VL-6.LC UVC lamp (254 nm)Vilber-LourmatCat\# 3111 0065 1VLX-3W dosimeterVilber-LourmatCat\# 5130 0011 1CX-254 254 nm sensorVilber-LourmatCat\# 5190 0001 1Polycarbonate filter (5 μm pore size)MilliporeCat\# TMTP01300

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sophie E. Polo (<sophie.polo@univ-paris-diderot.fr>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines {#sec4.3.1}

All U2OS (American Type Culture Collection ATCC HTB-96, human osteosarcoma, female) and NIH/3T3 (ATCC CRL-1658, mouse embryonic fibroblast, male) cell lines were grown at 37°C and 5% CO~2~ in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum (EUROBIO), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen) and the appropriate selection antibiotics.Stable cell line (reference if not generated in this study)Selection antibioticsU2OS H2A.X-SNAP WT formG418U2OS H2A.X-SNAP S139A mutantG418U2OS H2A.X-SNAP S139E mutantG418U2OS H2A.Z.1-SNAPG418U2OS H2A.Z.2-SNAPG418U2OS H2A-SNAPG418U2OS H3.3-SNAP ([@bib22])G418NIH/3T3 H2A.X-SNAP + GFP-DDB2G418 + Hygromycin

Antibiotics: G418 (100 μg/mL for U2OS, 500 μg/mL for NIH/3T3, Euromedex), Hygromycin (200 μg/mL, Euromedex).

Method Details {#sec4.4}
--------------

### Drug treatments {#sec4.4.1}

Transcription inhibition was performed either by adding DRB (100 μM final concentration, Sigma-Aldrich), alpha-Amanitin (AMA, 20 μg/mL final concentration, Sigma-Aldrich) or Flavopiridol hydrochloride hydrate (FLV, 10 μM final concentration, Sigma-Aldrich) to the culture medium at 37°C 4 h before harvesting the cells. Inhibition of replicative synthesis was performed by adding Aphidicolin (Aphi, 1 μg/mL final concentration, Sigma-Aldrich) to the culture medium at 37°C 5 h before harvesting the cells. For ATR and ATM inhibition, cells were incubated with 2 μM ATR inhibitor AZ20 (Selleckchem) or 10 μM ATM inhibitor KU55933 (Tocris Bioscience) 1h before subsequent cell treatment. For FACT trapping, cells were incubated with 2 μM CBL0137 (Bertin Pharma) 15 min before subsequent cell treatment. The DSB-inducing agent neocarzinostatin (NCS, Sigma-Aldrich) was applied for 15 min at 50 ng/ml followed by 1 h recovery in fresh medium. For cell synchronization in late G2, cells were treated for 16 h with 2 mM Thymidine (Sigma-Aldrich), followed by 6 h release in fresh medium and 22 h treatment with the cdk1 inhibitor RO-3306 (10 μM final, Sigma-Aldrich).

### SNAP-tag labeling of histone proteins {#sec4.4.2}

For specific labeling of newly-synthesized histones, pre-existing SNAP-tagged histones were first quenched by incubating cells with 10 μM non-fluorescent SNAP reagent (SNAP-Cell Block, New England Biolabs) for 30 min (quench) followed by a 30 min-wash in fresh medium and a 2 h-chase. The SNAP-tagged histones neo-synthesized during the chase were then pulse-labeled by incubation with 2 μM red-fluorescent SNAP reagent (SNAP-Cell TMR-Star, New England Biolabs) for 15 min followed by 1h to 1h30-wash in fresh medium. Cells were pre-extracted with Triton detergent before fixation (see Immunofluorescence section for details). If cells were subject to local UVC irradiation, irradiation was performed immediately before the pulse. When transcription inhibitors were used, they were added to the medium at the quench step and kept throughout the experiment. For total labeling of SNAP-tagged histones, the quench step was omitted and cells were pulsed with SNAP-Cell TMR-Star immediately before harvesting. Total H2A.Z is also revealed by immunostaining with antibodies against H2A.Z amino- or carboxy-terminus (Nt/Ct)

### siRNA and plasmid transfections {#sec4.4.3}

siRNAs purchased from Eurofins MWG Operon were transfected into cells using Lipofectamine RNAiMAX (Invitrogen) following manufacturer's instructions. The final concentration of siRNA in the culture medium was 50 nM. Cells were analyzed and/or harvested 48 to 72 h post-transfection.siRNATarget sequence**siANP32E\#1**^5′^AUGGAUUUGAUCAGGAGGAUA^3′^**siANP32E\#2**^5′^UUGGAGCUUAGUGAUAAUAUA^3′^**siCAF-1 p60**^5′^AAUCUUGCUCGUCAUACCAAA^3′^**siFACT\#1**1:1 combination of siSPT16: ^5′^GGAAUUAAGACAUGGUGUG^3′^ and siSSRP1: ^5′^GAUGAGAUCUCCUUUGUCA^3′^**siFACT\#2**1:1 combination of siSPT16: ^5′^ACAUCAGCAUAUGCAUGAC^3′^ and siSSRP1: ^5′^UGAGGUGACACUGGAAUUC^3′^**siFACT\#3**1:1 combination of siSPT16: ^5′^ACCGGAGUAAUCCGAAACUGA^3′^ and siSSRP1: ^5′^UUCGUUGACUCUGAACAUGAA^3′^**siH2A.X**^5′^CAACAAGAAGACGCGAAUC^3′^**siHIRA**^5′^GGAGAUGACAAACUGAUUA^3′^**siINO80\#1**^5′^GGAGUUAUUUGAACGGCAA^3′^**siINO80\#2**^5′^ACUUGGUCUCCAUUUCAUA^3′^**siLUC (Luciferase)**^5′^CGUACGCGGAAUACUUCGA^3′^**siNAP1+2**1:1 combination of siNAP1: ^5′^UCACUUUGAACCCAAUG^3′^ and siNAP2: ^5′^UGAAAUCAGAACCAGAUAA^3′^**siPCNA\#1**^5′^CCGAGAUCUCAGCCAUAUU^3′^**siPCNA\#2**^5′^GGAGGAAGCUGUUACCAUA^3′^**siXPG\#1**^5′^GAAAGAAGAUGCUAAACGU^3′^**siXPG\#2**^5′^GGAGAAAGAAUUUGAGCUA^3′^

For stable cell line establishment, cells were transfected with plasmid DNA (1 μg/ml final) using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions 48 h before antibiotic selection of clones. All constructs were verified by direct sequencing and/or restriction digests. Cloning details and primer sequences (Sigma-Aldrich) are available upon request.PlasmidConstruct details**H2A.X-SNAP (WT)***H2AFX* coding sequence cloned into pSNAPm (New England Biolabs)**H2A.X-SNAP (S139A)***H2AFX* coding sequence with insertion of a mutation S139A (TCC to GCG) cloned into pSNAPm (New England Biolabs)**H2A.X-SNAP (S139E)***H2AFX* coding sequence with insertion of a mutation S139E (TCC to GAG) cloned into pSNAPm (New England Biolabs)**H2A.Z.1-SNAP***H2AFZ* coding sequence cloned into pSNAPm (New England Biolabs)**H2A.Z.2-SNAP***H2AFV* coding sequence cloned into pSNAPm (New England Biolabs)**H2A-SNAP***HIST1H2AM* coding sequence cloned into pSNAPm (New England Biolabs)**H3.3-SNAP***H3F3B* coding sequence cloned into pSNAPm (New England Biolabs) ([@bib22])**GFP-DDB2***DDB2* coding sequence (Montpellier Genomic Collections) subcloned into GFP-XPC plasmid ([@bib54]) replacing XPC ([@bib3])

All the coding sequences for histone variants and repair factors are of human origin.

### UVC irradiation {#sec4.4.4}

Cells grown on glass coverslips (Menzel Gläser) were irradiated with UVC (254 nm) using a low-pressure mercury lamp. Conditions were set using a VLX-3W dosimeter (Vilber-Lourmat). For global UVC irradiation, cells in Phosphate Buffer Saline (PBS) were exposed to UVC doses ranging from 4 to 12 J/m^2^ by varying the duration of exposure. For local UVC irradiation, cells were covered with a polycarbonate filter (5 μm pore size, Millipore) and irradiated with 150 J/m^2^ UVC unless indicated otherwise. Only 2% of the UVC light goes through these micropore filters.

### UVA laser micro-irradiation {#sec4.4.5}

Cells grown on glass coverslips (Menzel Gläser) were presensitized with 10 μM 5-bromo-2′-deoxyuridine (BrdU, Sigma-Aldrich) for 24 hr at 37°C. Damage was introduced with a 405 nm laser diode (3 mW) focused through a Plan-Apochromat 63x /1.4 oil objective to yield a spot size of 0.5-1 μm using a LSM710 NLO confocal microscope (Zeiss) and the following laser settings: 40% power, 50 iterations, scan speed 12.6 μsec/pixel.

### Cell extracts and western blot {#sec4.4.6}

Total extracts were obtained by scraping cells in Laemmli buffer (50 mM Tris HCl pH 6.8, 1.6% SDS (Sodium Dodecyl Sulfate), 8% glycerol, 4% β-mercaptoethanol, 0.0025% bromophenol blue) followed by 5 min denaturation at 95°C. Cytosolic and nuclear extracts were obtained as previously described ([@bib51]). The chromatin fraction was prepared by addition of benzonase (Novagen) to the pellet after nuclear extraction.

For western blot analysis, extracts were run on 4%--20% Mini-PROTEAN TGX gels (Bio-Rad) in running buffer (200 mM glycine, 25 mM Tris, 0.1% SDS) and transferred onto nitrocellulose membranes (Amersham) with a Trans-Blot SD semidry transfer cell (Bio-Rad). Total proteins were revealed by reversible protein stain (Pierce). Proteins of interest were probed using the appropriate primary and HRP (Horse Radish Peroxidase)-conjugated secondary antibodies (Jackson Immunoresearch), detected using Super-Signal West Pico or Femto chemi-luminescence substrates (Pierce). Alternatively, when fluorescence detection was used instead of chemi-luminescence, total proteins were revealed with REVERT total protein stain, secondary antibodies were conjugated to IRDye 680RD or 800CW and imaging was performed with Odyssey Fc-imager (LI-COR Biosciences).AntibodySpeciesDilutionApplicationSupplier (reference)**Primary53BP1**Rabbit1:1000WB; IFNovus Biologicals (NB100-304)**ANP32E**Rabbit1:100WBSigma-Aldrich (SAB2100124)**ANP32E**Rabbit1:500WBMyBioSource (MBS9214243)**ATR**Goat1:300; 1:50WB; IFSanta Cruz Biotechnology (sc-1887)**CAF-1 p60**Rabbit1:500IFAbcam (ab109442)**CAF-1 p150**Mouse1:500IFAbcam (ab24746)**CPD**Mouse1:1000IFKamiya Biomedical Company (MC-062)**DDB2**Mouse1:200WBAbcam (ab51017)**GFP**Mouse1:1000WBRoche (11814460001)**H2A**Rabbit1:1000WBMillipore (07-146)**H2A.X**Rabbit1:4000; 1:1000WB; IFAbcam (ab11175)**γH2A.X**Mouse1:1000IFMillipore (05-636)**γH2A.X**Rabbit1:1000; 1:250WB; IFCell Signaling technology (2577)**H2A.Z**Sheep1:1000WBMillipore (09-862)**H2A.Z Ct**Rabbit1:1000IFActive motif (39113)**H2A.Z Nt**Rabbit1:500IFGeneTex (GTX108298)**H3.3**Rabbit1:1000WBMillipore (09-838)**HIRA**Mouse1:100IFActive Motif (39557)**INO80**Rabbit1:1000WBBethyl Laboratories (A303-371A)**MDC1**Rabbit1:1000 1:10 000IF; WBAbcam (ab11171)**NAP1**Rabbit1:4000WBActive Motif (39842)**NAP2**Rabbit1:2000WBBethyl Laboratories (A304-579A)**PARP1**Rabbit1:1000WBCell Signaling Technology (9542S)**PCNA**Mouse1:1000WB; IFDako (M0879)**RNAPII Ser2-P**Rabbit1:10 000WBAbcam (ab5095)**SNAP**Rabbit1:1000WB; IFPierce Antibodies (CAB4255)**SPT16 (FACT subunit)**Rabbit1:500; 1:100WB; IFSanta Cruz Biotechnology (sc-28734)**SSRP1 (FACT subunit)**Mouse1:500; 1:1000WB; IFOzyme (BLE609701)**Tubulin**Mouse1:10 000WBSigma-Aldrich (T9026)**XPA**Mouse1:400IFBD Biosciences (556453)**XPB**Rabbit1:400IFSanta Cruz Biotechnology (sc-293)**XPG**Rabbit1:500WBBethyl Laboratories (A301-484A)**SecondaryAnti-Mouse HRP**Goat1:10 000WBJackson Immunoresearch (115-035-068)**Anti-Rabbit HRP**Donkey1:10 000WBJackson Immunoresearch (711-035-152)**Anti-goat HRP**Donkey1:10 000WBSanta Cruz Biotechnology (sc-2020)**Anti-Sheep HRP**Donkey1:10 000WBJackson Immunoresearch (711-035-147)**Anti-Mouse IRDye 680RD**Goat1:15 000WBLI-COR Biosciences (926-68070)**Anti-Mouse IRDye 800CW**Goat1:15 000WBLI-COR Biosciences (926-32210)**Anti-Rabbit IRDye 680RD**Goat1:15 000WBLI-COR Biosciences (926-68071)**Anti-Rabbit IRDye 800CW**Goat1:15 000WBLI-COR Biosciences (926-32211)**Anti-Rabbit Alexa Fluor 488**Goat1:1000IFInvitrogen (A11034)**Anti-Rabbit Alexa Fluor 594**Goat1:1000IFInvitrogen (A11037)**Anti-Rabbit Alexa Fluor 647**Goat1:1000IFInvitrogen (A21245)**Anti-Rabbit Alexa Fluor 680**Goat1:1000IFInvitrogen (A21109)**Anti-Mouse Alexa Fluor 488**Goat1:1000IFInvitrogen (A11029)**Anti-Mouse Alexa Fluor 594**Goat1:1000IFInvitrogen (A11032)**Anti-Mouse Alexa Fluor 680**Goat1:1000IFInvitrogen (A21058)**Anti-Goat Alexa Fluor 488**Donkey1:1000IFInvitrogen (A11055)**Anti-Mouse Alexa Fluor 647**Donkey1:1000IFInvitrogen (A31571)

### Immunofluorescence and image acquisition {#sec4.4.7}

Cells grown on sterile round glass coverslips 12 mm diameter, thickness No.1.5 (Menzel Gläser) were either fixed directly with 2% paraformaldehyde (PFA, Electron Microscopy Sciences) and permeabilized with 0.5% Triton X-100 in PBS or first pre-extracted with 0.5% Triton X-100 in CSK buffer (Cytoskeletal buffer: 10 mM PIPES pH 7.0, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl~2~) and then fixed with 2% PFA to remove soluble proteins (not bound to chromatin). For CPD staining, DNA was denatured with 0.5 M NaOH for 5 min. For PCNA staining, cells were treated with Methanol (Prolabo) for 15 min at −20°C. Samples were blocked in 5% BSA (Bovine Serum Albumin, Sigma-Aldrich) in PBS supplemented with 0.1% Tween 20 (Euromedex) before incubation with primary antibodies and secondary antibodies conjugated to Alexa Fluor 488, 594, 647 or 680 (Invitrogen). The specificity of H2A.Z Nt and Ct antibodies in immunofluorescence was verified upon H2A.Z knock-down by siRNA (data not shown).

Coverslips were mounted in Vectashield medium with DAPI (Vector Laboratories) and observed with a Leica DMI6000 epifluorescence microscope using a Plan-Apochromat 40x/1.3 or 63x/1.4 oil objective. Images were captured using a CCD camera (Photometrics) and Metamorph software. For confocal images, we used a Zeiss LSM710 confocal microscope with a Plan-Apochromat 63x/1.4 oil objective and Zen software. Images were mounted with Adobe Photoshop applying the same treatment of fluorescence levels to all images from the same experiment except for [Figure 5](#fig5){ref-type="fig"}B where intensities in the red channel (TMR) were adjusted on a cell-by-cell basis because of variable levels of SNAP-tagged H2A.Z in the cell population.

### Visualization of replicative and repair synthesis {#sec4.4.8}

To visualize replicative synthesis, EdU (5-Ethynyl-2′-deoxyUridine) was incorporated into cells during 15 min (10 μM final concentration) and revealed using the Click-iT EdU Alexa Fluor 594 (or 647) Imaging kit (Invitrogen) according to manufacturer's instructions. To visualize repair synthesis, EdU (10 μM final concentration) was incorporated into cells during 4 h immediately after local UVC irradiation and revealed using the same kit, before CPD labeling by immunofluorescence. For experiments shown in [Figures 6](#fig6){ref-type="fig"}B--6E, EdU incorporation was for 2 h post UVC irradiation and replicating cells showing pan-nuclear EdU staining were excluded from the analysis.

### Nascent RNA labeling {#sec4.4.9}

Cells were incubated in DMEM supplemented with 0.5 mM EU (EthynylUridine) for 45 min, rinsed in cold medium and in PBS before fixation in 2% paraformaldehyde. EU incorporation was revealed with Click-iT RNA Imaging kits (Invitrogen) using Alexa Fluor 594 dye according to manufacturer's instructions.

### Flow cytometry {#sec4.4.10}

Cells were fixed in ice-cold 70% ethanol before DNA staining with 50 μg/mL propidium iodide (Sigma-Aldrich) in PBS containing 0.05% Tween 20 and 0.5 mg/mL RNaseA (USB/Affymetrix). DNA content was analyzed by flow cytometry using a FACS Calibur Flow Cytometer (BD Biosciences) and FlowJo Software (TreeStar).

### Colony-Forming Assays {#sec4.4.11}

Cells were replated 48 h after siRNA transfection and exposed to global UVC irradiation (4, 8 and 12 J/m^2^) the following day. Colonies were stained 10 days later with 0.5% crystal violet/20% ethanol and counted. Results were normalized to plating efficiencies.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Image analyses {#sec4.5.1}

ImageJ (U. S. National Institutes of Health, Bethesda, Maryland, USA, <https://imagej.nih.gov/ij/>) and ICY *(*Institut Pasteur, Paris, France, <http://icy.bioimageanalysis.org/>) softwares were used for image analysis. UV damage sites were delineated based on XPA, XPB, CPD or EdU staining (repair synthesis) and nuclei were delineated based on DAPI staining. Replicating cells were excluded based on pan-nuclear EdU staining ([Figure 6](#fig6){ref-type="fig"}). CPD levels at UV sites ([Figure S5](#mmc1){ref-type="supplementary-material"}G) were normalized to the average value obtained in siLUC control condition. To calculate the percentage of H2A.Z-SNAP loss at UV damage sites ([Figure S5](#mmc1){ref-type="supplementary-material"}G), total H2A.Z-SNAP levels (TMR-Star labeling) were normalized to DAPI staining and measured at UV sites relative to the entire nucleus. This ratio was subtracted from 1 and the result was then multiplied by 100.

Percentages of positively stained cells (i.e., showing visually detectable enrichment of the signal of interest at UV sites or replication foci) were obtained by scoring at least 100 cells in each experiment unless indicated otherwise. In experiments using transcription inhibitors, only cells showing above background TMR levels were scored.

### Statistical analyses {#sec4.5.2}

Statistical tests were performed using GraphPad Prism. Loss or enrichment of H2A.X and H2A.Z at UV sites relative to the whole nucleus was compared to a theoretical mean of 1 by one-sample t tests. P values for mean comparisons between two groups were calculated with a Student's t test with Welch's correction when necessary. Multiple comparisons were performed by one-way ANOVA with Bonferroni post-tests. Comparisons of clonogenic survival and CPD removal kinetics were based on non-linear regression with a polynomial quadratic model. ns: non-significant, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Statistical parameters including sample size (n) and dispersion of the data (SD or SEM) are indicated in the figure legends.

Data and Software Availability {#sec4.6}
------------------------------

Raw data files are deposited on Mendeley Data (<https://doi.org/10.17632/gz5xtcyxzj.1>).
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